Valneva SE (VALN)

[p0]

CDC study on rMNA (Pfizer-BioNTech+Moderna)
https://www.cdc.gov/

https://www.bmj.com/content/379/bmj-2022-072141

Participants 893?461 adults (≥18 years) admitted to one of 261 hospitals or to one of 272 emergency department
or 119 urgent care centers for covid-like illness tested for SARS-CoV-2.

Main outcome measures The main outcome was waning of vaccine effectiveness with
BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine during the omicron and delta periods,
and the period before delta was dominant using logistic regression conditioned on
calendar week and geographic area while adjusting for age, race, ethnicity, local virus circulation,
immunocompromised status, and likelihood of being vaccinated.

Results 45?903 people admitted to hospital with covid-19 (cases) were compared with
213?103 people with covid-like illness who tested negative for SARS-CoV-2 (controls),
and 103?287 people admitted to emergency department or urgent care with covid-19 (cases)
were compared with 531?168 people with covid-like illness who tested negative for SARS-CoV-2.

In the omicron period, vaccine effectiveness against covid-19 requiring admission
to hospital was 89% (95% confidence interval 88% to 90%) within two months after dose 3
but waned to 66% (63% to 68%) by four to five months.
Vaccine effectiveness of three doses against emergency department or urgent care visits
was 83% (82% to 84%) initially but waned to 46% (44% to 49%) by four to five months.
Waning was evident in all subgroups, including young adults and individuals who
were not immunocompromised; although waning was morein people who were
immunocompromised.
Vaccine effectiveness increased among most groups after a fourth dose in whom this booster was recommended.

Conclusions Effectiveness of mRNA vaccines against moderate and severe covid-19 waned with time after vaccination.

_______________________
"The results confirm the low efficacy of basic immunization with the two U.S.-approved mRNA
vaccines from Pfizer/Biontech and Moderna. Protection against hospitalization was
only 73 percent in the first two months after the second dose (versus 96 percent in the delta wave).
The weak protective effect of basic immunization continues to wane over time: After six to eight months,
the protective effect against hospitalization was only 48 percent,
and after more than 14 months, it was just 19 percent," reported the "Deutsches Ärzteblatt."

____ OT
https://www.medrxiv.org/content/10.1101/2022.07.05.22277189v1.full
https://www.cell.com/iscience/fulltext/S2589-0042(22)01119-1